Targets › PDE4A
27 programs from 26 companies in 75 trials: 41 Phase 2, 15 Phase 3, 10 Phase 1, 9 Phase 4; Immunology, Other, Genitourinary; next expected readout Nov 2026.
Hydrolyzes the second messenger 3',5'-cyclic AMP (cAMP), which is a key regulator of many important physiological processes..; FUNCTION: [Isoform 1]: Efficiently hydrolyzes cAMP..; FUNCTION: [Isoform 2]: Efficiently hydrolyzes cAMP..; FUNCTION: [Isoform 3]: Efficiently hydrolyzes cAMP. The phosphodiesterase activity is not affected by calcium, calmodulin or cyclic GMP (cGMP) levels. Does not hydrolyze cGMP..;…. (UniProt, P27815)
Open in Phaseline: the race on PDE4A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| St Joseph University, Beirut, Lebanon | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Lumbar Radiculopathy | Dec 2026 |
| Integrative Skin Science and Research | Roflumilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 4 | ITCH | Aug 2027 |
| VA Office of Research and Development | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 4 | Diabetic Kidney Disease | Jan 2028 |
| Vastra Gotaland Region | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| Massachusetts General Hospital | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 4 | PHP Ia | Apr 2030 |
| Cairo University | Crisaborole Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Vitiligo | Nov 2026 |
| Al-Azhar University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Chronic Kidney Diseases | Dec 2026 |
| Ganzhou Hemay Pharmaceutical | Hemay005 Phosphodiesterase 4 (PDE4) inhibitor | PDE4A, PDE4B, PDE4C, PDE4D | Phase 3 | Behçet's Disease; Moderate to Severe Ulcerative Colitis; Psoriasis | Dec 2026 |
| Tanta University | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | IBS - Irritable Bowel Syndrome; Rheumatoid Arthritis | May 2027 |
| Amgen | Apremilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Plaque Psoriasis; Active Juvenile Psoriatic Arthritis; Behçet Disease; Behçet's Disease … | Mar 2028 |
| Arcutis Biotherapeutics | Roflumilast Phosphodiesterase 4 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C | Phase 3 | Atopic Dermatitis; Chronic Plaque Psoriasis; Depressive Disorder, Major; Fragile X Syndrome … | Apr 2028 |
| Merck & Co. (MSD) | Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 3 | Pulmonary Disease, Chronic Obstructive | Apr 2029 |
| University of Washington | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Medication-related Osteonecrosis of the Jaw | – |
| Beni-Suef University | pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 3 | Embryo Transfer | – |
| Vanderbilt University Medical Center | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Pseudohypoparathyroidism | Dec 2026 |
| Mostafa Bahaa | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Epilepsy | Dec 2026 |
| Yunfeng Xia | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Restless Leg Syndrome Due to Uraemia | Dec 2026 |
| Ihab Elsayed Hassan | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Inflammatory Bowel Diseases | Jan 2027 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Ensifentrine (MK-5884) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis Bronchiectasis | Mar 2027 |
| Beni-Suef University | Aminophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Acute Calculous Anuria; Pediatric Urolithiasis; Renal Stones | Mar 2027 |
| University Hospital, Limoges | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Medication-related Osteonecrosis of the Jaw (MRONJ) | Apr 2027 |
| MediciNova | Ibudilast (MN-166) Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 2 | Amyotrophic Lateral Sclerosis | Apr 2027 |
| Stanford University | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Hypophosphatemia | May 2027 |
| M.D. Anderson Cancer Center | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Lymphedema; Fibrosis Syndrome | May 2029 |
| University Health Network, Toronto | Pentoxifylline Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor | ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3A | Phase 2 | Non-Small Cell Lung Cancer | Nov 2031 |
| Medical College of Wisconsin | Theophylline Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist | PDE4A, PDE4D, PDE4B, PDE4C, PDE3A | Phase 1 | Acute Kidney Injury | May 2027 |
Alcohol Use Disorder (5) Rheumatoid Arthritis (3) Behçet's Disease (2) Pseudohypoparathyroidism (2) Acute Kidney Injury (2) Head and Neck Squamous Cell Carcinoma (2) Atopic Dermatitis (2) Hidradenitis Suppurativa (HS) (2) Plaque Psoriasis (1) Active Juvenile Psoriatic Arthritis (1) Behçet Disease (1) Recurrent Aphtous Stomatitis (1)
small molecule (27)
Beni-Suef University (2) Amgen (1) University of Washington (1) University Hospital, Limoges (1) MediciNova (1) Stanford University (1) Mostafa Bahaa (1) M.D. Anderson Cancer Center (1) Vastra Gotaland Region (1) VA Office of Research and Development (1) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1) Ganzhou Hemay Pharmaceutical (1) Ihab Elsayed Hassan (1) Vanderbilt University Medical Center (1) Cairo University (1) University of Pennsylvania (1) Al-Azhar University (1) Merck & Co. (MSD) (1) Yunfeng Xia (1) Medical College of Wisconsin (1)
PDE3A (22) PDE5A (14) PDE4D (13) PDE4B (13) PDE4C (13) ADORA2B (11) ADORA2A (11) SLC29A1 (3) PDE6H (3) CHRNA4 (1) OPRK1 (1) OPRD1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.